Key Insights

Highlights

Success Rate

96% trial completion (above average)

Published Results

135 trials with published results (16%)

Research Maturity

677 completed trials (78% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

3.5%

30 terminated out of 865 trials

Success Rate

95.8%

+9.2% vs benchmark

Late-Stage Pipeline

27%

233 trials in Phase 3/4

Results Transparency

20%

135 of 677 completed with results

Key Signals

135 with results96% success30 terminated

Data Visualizations

Phase Distribution

723Total
Not Applicable (194)
Early P 1 (3)
P 1 (200)
P 2 (93)
P 3 (109)
P 4 (124)

Trial Status

Completed677
Unknown79
Terminated30
Withdrawn24
Recruiting22
Active Not Recruiting17

Trial Success Rate

95.8%

Benchmark: 86.6%

Based on 677 completed trials

Clinical Trials (865)

Showing 20 of 20 trials
NCT00001645RecruitingPrimary

Evaluation, Treatment and Monitoring of Patients With a Known or Suspected Parasitic Infection

NCT02471378RecruitingPrimary

Laboratory Evaluation of Pregnancy Malaria Vaccine Candidates/In-vitro Testing of Pregnancy Malaria Vaccine Candidates

NCT03937817Recruiting

Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants

NCT06461026Phase 1CompletedPrimary

L9LS MAb in Malian Infants

NCT06607003Phase 1RecruitingPrimary

Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays

NCT07758985Phase 1RecruitingPrimary

Safety, Tolerability, Pharmacokinetics, and Mosquitocidal Activity of Lotilaner in Healthy Participants in Mali.

NCT01555255CompletedPrimary

Malaria Rapid Diagnostic Tests (RDTs) in Pregnancy: Detection of Placental Malaria

NCT05652504Phase 1WithdrawnPrimary

Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)

NCT05050825Not ApplicableCompletedPrimary

Validation of a CDSA Strategy to Reduce Antibiotic Prescription in Senegal

NCT07246525Phase 4Not Yet RecruitingPrimary

Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community Transmission

NCT05889052Completed

Perennial Malaria Chemoprevention (PMC) in Cameroon

NCT05856357CompletedPrimary

Perennial Malaria Chemoprevention (PMC) in Côte d'Ivoire

NCT07798583Phase 3Not Yet RecruitingPrimary

OPTIMAL LEAP: Optimizing Dihydroartemisinin-Piperaquine IPTsc Intervals to Advance Learning, Executive Function, Attendance, and Antimalarial Resistance Surveillance in Kenyan Schoolchildren

NCT02639299RecruitingPrimary

Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge

NCT06069544Phase 1CompletedPrimary

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

NCT06560853Not ApplicableActive Not RecruitingPrimary

Evaluation of a Comprehensive School Health Programme in Zambia

NCT01168271RecruitingPrimary

Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali

NCT06735209Phase 1CompletedPrimary

First-in-Human PfSPZ-LARC2 Vaccination/CHMI

NCT06854042Phase 1Active Not RecruitingPrimary

A Study of Oral E1018 in Healthy Adult Participants

NCT05400746Early Phase 1TerminatedPrimary

A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK

Scroll to load more

Research Network

Activity Timeline